Valneva Withdraws U.S. IXCHIQ Chikungunya Filings After FDA Clinical Hold

Valneva ( (VALN) ) has provided an update.

On January 19, 2026, Valneva announced it had voluntarily withdrawn its biologics license application and Investigational New Drug application for its chikungunya vaccine IXCHIQ in the United States, after the FDA suspended the product’s U.S. license in August 2025 and subsequently placed the IND on clinical hold following a newly reported serious adverse event abroad. The reported case involved a younger adult who had received three concomitant vaccines, including IXCHIQ, and while Valneva said a plausible link to IXCHIQ could not be ruled out, causality has not been determined; the company is seeking more information and will proceed with planned post-marketing clinical activities subject to further discussions with regulators. IXCHIQ remains licensed in Europe, Canada, the UK and Brazil, where it is aimed primarily at travelers and medically justified high‑risk groups in endemic regions, and Valneva continues to review the global commercial opportunity for the vaccine while emphasizing its view that the product’s benefit‑risk profile remains favorable in endemic and outbreak settings, a stance that will be closely watched by regulators, healthcare providers and investors given chikungunya’s growing public health and economic burden.

The most recent analyst rating on (VALN) stock is a Hold with a $10.00 price target. To see the full list of analyst forecasts on Valneva stock, see the VALN Stock Forecast page.

Spark’s Take on VALN Stock

According to Spark, TipRanks’ AI Analyst, VALN is a Neutral.

Valneva’s overall stock score reflects significant financial challenges, including negative profitability and cash flow issues. While technical indicators show neutral momentum, and the earnings call highlighted some positive developments, the company’s high leverage and ongoing losses weigh heavily on the score. Promising clinical advancements provide potential for future growth but are not enough to offset current financial concerns.

To see Spark’s full report on VALN stock, click here.

More about Valneva

Valneva SE is a specialty vaccine company that develops, manufactures and commercializes prophylactic vaccines for infectious diseases with unmet medical needs. The French-headquartered group focuses on first-, best- or only-in-class vaccine solutions, currently markets three proprietary travel vaccines, and is advancing a pipeline that includes the only Lyme disease vaccine candidate in advanced clinical development in partnership with Pfizer, as well as what it describes as the world’s most clinically advanced Shigella vaccine candidate and other programs targeting global public health threats.

Average Trading Volume: 22,977

Technical Sentiment Signal: Buy

Current Market Cap: $879.2M

See more insights into VALN stock on TipRanks’ Stock Analysis page.